Investigating how certain factors drive lethal prostate cancer
Mechanisms and therapeutic targeting of lethal prostate cancer master regulator transcription factors
This study is looking at how a specific protein called GATA2 affects the growth and spread of advanced prostate cancer, with the hope that understanding this could help develop new treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11030814 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms behind advanced prostate cancer, particularly how a master regulator transcription factor called GATA2 contributes to the disease's progression. By studying the role of GATA2 in cancer cell behavior, the research aims to uncover how it influences the aggressiveness and metastatic potential of prostate cancer. The approach includes advanced computational and functional studies to analyze gene expression and cellular behavior in prostate cancer cells. Patients may benefit from insights that could lead to new therapeutic strategies targeting these mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are American men diagnosed with advanced or metastatic prostate cancer, particularly those whose disease has become resistant to standard therapies.
Not a fit: Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target the mechanisms driving lethal prostate cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting transcription factors in cancer treatment, suggesting that this approach may lead to significant advancements in managing lethal prostate cancer.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Domingo-Domenech, Josep Maria — Mayo Clinic Rochester
- Study coordinator: Domingo-Domenech, Josep Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.